Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TDM-guided polymyxin B therapy for carbapenem-resistant organism sepsis
ChiCTR2100043208Phase 4Recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Feb 2021
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of polymyxin B in sepsis and Infection (2 arms), sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoint: 14-day improvement rate. Started Feb 2021; status: recruiting.
02
Drugs
polymyxin B
03
Conditions
sepsisInfection
Beyond the preview
Go deeper on ChiCTR2100043208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100043208.